AstraZeneca's drug pricing deal with the White House Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 13 October, 2025

The only optichannel HCP engagement platform in biopharma helps you reimagine what’s possible—driving agile, real-time campaigns with such clear ROI that 100% of clients renew. sponsored by PharmaForceIQ

presented by In sight: Ad­vanc­ing cell ther­a­py for reti­nal dis­ease

news Bioregnum Is the worst over? Biopharma dealmaking shows an uptick in third quarter Novo Nordisk quits cell therapy as restructure continues Gilead, Arcus’ TIGIT approach exceeds two years of median survival in Phase 2 gastric cancer trial Regeneron heads to FDA to seek approval for hearing loss gene therapy AstraZeneca strikes drug pricing deal with the White House, the second pharma to do so

Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Biopharma is entering a new era of AI-driven discovery and precision medicine — but growth is challenged by regulatory shifts and global uncertainty. Join us in London to hear from the leaders shaping what’s next. UTMs:

endpoints pharma Biosecure is back. It doesn't appear as threatening to biotechs as before Head of FDA's orphan drug office is removed from role Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way J&J is in discussions to buy out Protagonist Therapeutics — report

in case you missed it 1. Biopharma is wagering billions of dollars that CAR-T therapy can be easier. Will it work this time? 2. Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition 3. Peer Review Shape's former CSO picks up tech role at Moderna; Lilly reels in Peter Marks 4. Cabaletta Bio says small number of autoimmune patients responded to its CAR-T without toxic preconditioning 5. News Briefing Satellos to run a trial for Duchenne pill in kids; Idorsia raises $81M 6. Samsara BioCapital eyes $200M opportunity fund 7. French non-profit bets on Duchenne gene therapy that comes in lower dose than Elevidys 8. Ypsomed spends $248M to gain its first US manufacturing site